ITGAX and metabolic dysfunction-associated steatohepatitis: Strikingly, SH42 did not affect KC numbers (Fig 5B and C), and did not prevent KC activation as evidenced by unchanged high levels of NASH‐associated MHCII+CD11c+‐activated KCs (Fig 5D and E) and MHCII−CD11c− resting KCs (Fig 5D and F).